- Premium Stock Alerts
- Posts
- Act Now! Pre-Market Gains - Time to Secure Profits!
Act Now! Pre-Market Gains - Time to Secure Profits!
Noor Saba
April 19, 2024
Don’t want emails from us anymore? Click here to unsubscribe
Hello Part-time Trader…👋
Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:
Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.
Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.
Top Pre-Market Movers: Identify early winners poised for a strong market opening.
Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.
FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.
Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.
Sponsored
Top 5 "Portfolio Supercharging" Stocks - Free Report from Zacks Investment Research
Zacks has a proven track record for picking big winners. And now, our team of experts has hand-selected, from thousands of companies, the 5 stocks they predict they have outsized gain-potential NOW and in the coming year.
Recent recommendations have climbed as high as +288%. In fact, our newest report could point to even bigger gains. These picks will surprise you and current market conditions could make our new recommendations even more profitable. This special arrangement is good for a limited time only.
I urge you to act now!
Happening Today
✓ 01:00 PM ET – U.S. Baker Hughes Oil Rig Count
✓ 01:00 PM ET – U.S. Baker Hughes Total Rig Count
✓ 03:30 PM ET – CFTC Crude Oil speculative net positions
✓ 03:30 PM ET – CFTC Gold speculative net positions
✓ 03:30 PM ET – CFTC Nasdaq 100 speculative net positions
✓ 03:30 PM ET – CFTC S&P 500 speculative net positions
PREMARKET SNAPSHOT 📈
Stock Futures show a mixed picture with the NASDAQ down nearly 0.6% leading the pre-market decline.
S&P500$5011.12 ⬇️ -0.22% | Dow$37775.38 ⬆️ 0.05% | NASDAQ$17394.314 ⬇️ -0.56% |
SECTOR SNAPSHOT ✨
Tech stocks lead the decline, falling 0.89% today, while utilities and communication services sectors shine with gains exceeding 0.5%.
NAME | PRICE | %CHANGE |
|---|---|---|
Consumer Discretionary | 1,398.81 | -0.71% 🔴 |
Consumer Staples | 786.80 | +0.41% 🟢 |
Energy | 717.95 | -0.22% 🔴 |
Financials | 662.89 | +0.40% 🟢 |
Health Care | 1,613.65 | +0.02% 🟢 |
Industrials | 1,021.45 | -0.35% 🔴 |
Materials | 560.65 | +0.03% 🟢 |
Real Estate | 224.07 | +0.02% 🟢 |
Information Technology | 3,611.67 | -0.89% 🔴 |
Communication Services | 286.30 | +0.66% 🟢 |
Utilities | 327.37 | +0.61% 🟢 |
Sponsored
NOW is the time to get in on this trillion-dollar megatrend
Now is the time to position yourself for the next round of explosive growth from what will soon be a trillion-dollar market. But don't chase yesterday's winners!
The AI hype is off the charts and some AI stocks have run so far that they are looking WAY overvalued. When they crash back down to earth, some investors could get hurt. I don't want that to happen to you! So I'm making our new special report on the best AI stocks to own now free for a limited time.
Get it here.
Unusual Volume
📈 SINTX Technologies Inc (SINT) jumped 7.24% to $0.04 on a whopping 432.25 million shares traded.
📈 Investors went wild, sending AGBA Group Holding Limited (AGBA) stock soaring 157.50% to $1.03 on a massive volume of 122.25 million shares. AGBA Group Holding Limited together with Triller Corp announced that they have entered into a definitive merger agreement to combine AGBA with Triller.
📈 Abnormal activity shook Bio-Path Holdings Inc (BPTH), pushing it up 29.63% to $4.20 on a whopping 83.14 million shares traded after announcing $1.2 million registered direct offering priced at-the-market under Nasdaq Rules.
📈 Fuelcell Energy Inc (FCEL) stock recently closed -6.93% lower at $0.93 on substantial volume of 69.17 million shares.
📈 Green Giant Inc (GGE) increase by 23.76% in a single trading session, with abnormally high trading volume of 66.53 million shares.
Sponsored
Free Stock Analysis Report: Shows You when to Buy or Sell Stocks
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
Analyze Any Stock Free
Premarket Movers
Trio Petroleum Corp. (TPET) experiences a substantial 31.59% surge in pre-market trading following the filing of 8-K form with the SEC.
SuperCom Ltd. (SPCB) sees a significant 20.08% increase, reaching a pre-market price of $0.28 after announcing the pricing of $2.9 million registered direct offering.
Ault Alliance, Inc. (AULT) demonstrates a noteworthy 20.36% surge, with a pre-market price of $0.29. The company reported that it has received an investment of $44 million to date from Ault & Company under the November 2023 securities purchase agreement.
Pre Market Gainers | Pre Market Change | Pre Market Volume |
|---|---|---|
EGOX | +40.00% | 13.63M |
TPET | +31.29% | 6.15M |
ZCMD | +84.14% | 2.96M |
HUBC | +16.28% | 2.67M |
SPCB | +20.08% | 1.84M |
AULT | +20.36% | 1.15M |
GDHG | +12.78% | 997.94K |
CEI | +8.11% | 914.97K |
YYAI | +8.13% | 908.22K |
WLGS | +28.30% | 534.52K |
Sponsored
Set aside 3 minutes now, and collect a monthly check for eternity
If you set aside just 3 minutes, right now, you could set yourself up for a near eternal monthly income stream with this "forever dividend stock". I've done over 31 years of due diligence, and this is without a doubt, the most reliable dividend stock money can buy. It's a stream of income you can pass down to your kids, your grandkids.
Click here to claim your "eternal income" FREE report.
Important FDA
Recently Announced
Johnson & Johnson (JNJ) achieved a breakthrough on April 5, 2024, as the FDA granted expanded use for their treatment Carvykti. This widens the scope of Carvykti's application to adult patients with relapsed or refractory multiple myeloma who have already undergone at least one prior line of therapy.
AbbVie (ABBV) celebrated a major milestone on April 5, 2024. Their drug ELAHERE, which previously received accelerated approval, has now secured full FDA approval for the treatment of certain ovarian cancer patients.
Bristol-Myers Squibb Co. (BMY) marked a significant achievement on April 5, 2024, with the FDA's approval of Opdivo. In combination with cisplatin-based chemotherapy, Opdivo is now a first-line treatment option for adult patients with unresectable or metastatic urothelial carcinoma.
Upcoming Announcements
ImmunityBio, Inc. (IBRX) has its sights set on April 23, 2024. That's the date the FDA is scheduled to announce its decision on N-803 plus BCG, a potential breakthrough therapy for high-risk non-muscle-invasive bladder cancer. The company's resubmitted BLA represents a significant hope for patients with this challenging condition.
Aquestive Therapeutics Inc. (AQST) is on the cusp of a major development. On April 28, 2024, the FDA will decide on the fate of Libervant, a potential treatment for seizure clusters in young children. This NDA submission could fill a critical gap in pediatric epilepsy treatment, and the company awaits the FDA's verdict with anticipation.
PharmaTher Holdings Ltd. (PHRRF.OB) holds its breath until April 29, 2024. That's when the FDA will rule on KETARX, a drug with potential applications in anesthesia, sedation, pain management, mental health, and neurological disorders. A positive ANDA decision could unlock new possibilities in various treatment areas, and the company eagerly awaits the outcome.
Happy investing,
Maeve Grace
Editor In Chief
Premium Trade Alerts
Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.
Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.
Join the conversation